Chronic kidney disease
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Annual screening in at-risk patients
Laboratory tests
- Serum creatinine with eGFR (CKD-EPI)
Urine tests
- Urine albumin:creatinine ratio (ACR) on a spot urine sample (preferably first morning urine)
Mild to moderate chronic kidney disease found (eGFR < 60), repeated at 3 months
Fasting laboratory tests
- FBC
- Reticulocyte countif neededThe search for complications begins at stage 3 or 3B: FBC with reticulocyte count and serum ferritin, the first-line test for iron deficiency, which is routinely associated [1].
- Serum ferritinif neededThe search for complications begins at stage 3 or 3B: FBC with reticulocyte count and serum ferritin, the first-line test for iron deficiency, which is routinely associated [1].
- Serum electrolytes
- Serum calcium
- Serum phosphate
- Bicarbonate
- Urea (reimbursed)
- Serum creatinine with eGFR
- Total serum protein
- Serum albumin
- Serum protein electrophoresis (and immunofixation as a reflex test)
- Lipid profile
- Fasting plasma glucose
- HIV serologyif neededDepending on the context (risk factor for HIV exposure): the HAS guide on chronic kidney disease cites it only in the pre-transplant work-up [1].
- Hepatitis C serology
- Hepatitis B serology: anti-HBs antibodies, anti-HBc antibodies (the procedure also includes HBsAg)
Urine tests
- Urine protein:creatinine ratio (spot sample)
- Urine albumin:creatinine ratio (ACR) on a spot urine sample
- Urine microscopy and culture
Follow-up of stage 3A chronic kidney disease (eGFR > 45)
Fasting laboratory tests
- Serum creatinine with eGFR
- Lipid profile
- Fasting plasma glucose
- FBCif needednon-French guidelineKDIGO (2026) considers it reasonable to look for anaemia and iron deficiency at least once a year from stage 3 [12], and the Australian general practice manual provides for a yearly blood count at this stage [5]. The HAS guide provides for blood count and serum ferritin only from stage 3B, except in people with diabetes, in whom it recommends screening for complications from stage 3A [1].
- Serum ferritinif needednon-French guidelineKDIGO (2026) considers it reasonable to look for anaemia and iron deficiency at least once a year from stage 3 [12], and the Australian general practice manual provides for a yearly blood count at this stage [5]. The HAS guide provides for blood count and serum ferritin only from stage 3B, except in people with diabetes, in whom it recommends screening for complications from stage 3A [1].
Urine tests
- Urine albumin:creatinine ratio (ACR) on a spot urine sample
- Or urine protein:creatinine ratio on a spot urine sample (kidney disease without albuminuria: HIV, monoclonal gammopathy, etc.)if neededKidney disease in which albuminuria may be absent (HIV infection, monoclonal gammopathy): the HAS guide accepts the ACR or the PCR for follow-up [1].
Follow-up of moderate stage 3B chronic kidney disease (eGFR between 30 and 44)
Twice-yearly tests
Fasting laboratory tests
- Serum creatinine with eGFR
- FBC with reticulocyte count
- Serum electrolytes
- Bicarbonate
- Serum calcium
- Serum phosphate
- Serum ferritin
- Transferrin saturation (if ferritin abnormal)if neededSecond-line, if serum ferritin is abnormal: iron and transferrin sampled in the morning, fasting, away from acute inflammation [1]; the laboratory may add it on its own after ferritin [10].
- Serum albumin
- Lipid profile (once a year)if neededOnce a year, according to the follow-up table of the HAS guide [1].
- Fasting plasma glucose (once a year)if neededOnce a year, in non-diabetic patients (follow-up table of the HAS guide) [1].
- HBsAg (if not vaccinated) or anti-HBs (if vaccinated) (every 3 years)if neededEvery 3 years at stage 3B: HBsAg if the patient is not vaccinated, anti-HBs antibodies if vaccinated (target > 10 IU/L) [1].
- PTHif neededFrequency according to the initial concentration and progression of CKD (HAS guide) [1]; outside the NABM indications in non-dialysed patients: write “NR” (not reimbursable in France) [13].
- 25-hydroxyvitamin D (first tests for phosphocalcic complications)if neededThe HAS guide places it in the search for phosphocalcic complications from stage 3B [1]; KDIGO suggests it may be measured from stage 3A [14]. Outside the NABM indications: write “NR” (not reimbursable in France) [13].
Urine tests
- Urine protein:creatinine ratio (spot sample)
Follow-up of severe stage 4 chronic kidney disease (eGFR between 15 and 29)
Three-monthly tests
Fasting laboratory tests
- Serum creatinine with eGFR
- FBC with reticulocyte count
- Serum electrolytes
- Bicarbonate
- Serum calcium
- Serum phosphate
- Serum ferritin
- Transferrin saturation (if ferritin abnormal)if neededSecond-line, if serum ferritin is abnormal: iron and transferrin sampled in the morning, fasting, away from acute inflammation [1]; the laboratory may add it on its own after ferritin [10].
- Serum albumin
- PTH
- Alkaline phosphatase
- Blood urea
- Lipid profile (once a year)if neededOnce a year, according to the follow-up table of the HAS guide [1].
- Fasting plasma glucose (once a year)if neededOnce a year, in non-diabetic patients (follow-up table of the HAS guide) [1].
- HBsAg (if not vaccinated) or anti-HBs (if vaccinated) (once a year)if neededOnce a year at stage 4: HBsAg if the patient is not vaccinated, anti-HBs antibodies if vaccinated (target > 10 IU/L) [1].
Urine tests
- Urine protein:creatinine ratio (spot sample)
Follow-up of severe stage 5 chronic kidney disease (eGFR < 15)
Monthly tests
Fasting laboratory tests
- Serum creatinine with eGFR
- FBC with reticulocyte count
- Serum electrolytes
- Bicarbonate
- Serum calcium
- Serum phosphate
- Serum ferritin
- Transferrin saturation (if ferritin abnormal)if neededSecond-line, if serum ferritin is abnormal: iron and transferrin sampled in the morning, fasting, away from acute inflammation [1]; the laboratory may add it on its own after ferritin [10].
- Serum albumin
- Alkaline phosphatase
- Blood urea
- PTH (every 3 to 6 months)if neededEvery 3 to 6 months at stage 5 (HAS guide, KDIGO) [1,14]; before dialysis, outside the NABM indications: write “NR” (not reimbursable in France) [13].
- PTH, reimbursed (dialysis patient)if neededIn dialysed patients, PTH monitoring falls within the NABM indications of code 0983: do not write “NR” (not reimbursable in France); before dialysis, use the previous line [13].
- Lipid profile (once a year)if neededOnce a year, according to the follow-up table of the HAS guide [1].
- Fasting plasma glucose (once a year)if neededOnce a year, in non-diabetic patients (follow-up table of the HAS guide) [1].
- HBsAg (if not vaccinated) or anti-HBs (if vaccinated) (once a year)if neededOnce a year at stage 5: HBsAg if the patient is not vaccinated, anti-HBs antibodies if vaccinated (target > 10 IU/L) [1].
Urine tests
- Urine protein:creatinine ratio (spot sample)
After starting or increasing an ACE inhibitor, an ARB (ARB) or finerenone
Laboratory tests, 2 to 4 weeks after the change
- Serum creatinine with eGFR
- Serum electrolytes (sodium, potassium)
- Sample at the laboratory rather than at home, without a prolonged tourniquet or muscle contraction (spurious hyperkalaemia).
- Serum potassium at 1 month then every 4 months (finerenone)if needednon-French guidelineOn finerenone: serum potassium 1 month after initiation then every 4 months; suspend if it exceeds 5.5 mmol/L [3].
Also consider
- High serum potassium on an ACE inhibitor or ARB? Hyperkalaemia after an ACE inhibitor, an ARB or finerenone falls under the page "Hyperkaliémie".
- Rising creatinine on an ACE inhibitor or ARB? If serum creatinine rises after the ACE inhibitor or ARB, see the page "Créatininémie élevée".
Sources (15)
- Guide du parcours de soins – Maladie rénale chronique de l’adulte (MRC)
- Académie nationale de médecine. Dépistage, prévention et prise en charge de la maladie rénale chronique. Rapport adopté le 14 avril 2026 (Massy Z, Ronco P, Ardaillou R).
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024;105(4S):S117-S314.
- National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management. NICE guideline NG203, publiée le 25 août 2021, mise à jour le 24 novembre 2021 (recommandations 1.1.20 à 1.1.24, 1.2.5, 1.3.4 et tableau 2, 1.5.5, 1.6.14, 1.6.18, 1.6.19, 1.7.3, 1.7.4, 1.12.1, 1.12.2 et 1.12.8, et leur justification).
- Kidney Health Australia. Chronic Kidney Disease (CKD) Management in Primary Care. 5e édition. Melbourne : Kidney Health Australia ; 2024 (manuel destiné à la médecine générale).
- US Preventive Services Task Force (Moyer VA). Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(8):567-70 (recommandation I ; déclarée périmée sur le site de l’USPSTF, mise à jour en cours, page consultée le 29/10/2026).
- Qaseem A, Hopkins RH Jr, Sweet DE, Starkey M, Shekelle P ; Clinical Guidelines Committee of the American College of Physicians. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;159(12):835-47.
- Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in CKD Work Group. KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int. 2022;102(6S):S129-S205.
- Société francophone de néphrologie, dialyse et transplantation (SFNDT), Commission Néphrologie clinique. Fiche complète vaccination et maladie rénale chronique, juin 2024.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 0591 (urée) et 2002 (coefficient de saturation de la transferrine).
- Institut national d'excellence en santé et en services sociaux (INESSS). Utilisation judicieuse des analyses biomédicales : dosage de l'urée sérique pour l'évaluation de la fonction rénale. Québec, septembre 2026.
- Babitt JL, Berns JS, Bozkurt B, et al. Executive summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney Int. 2026;109(1):44-56.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 0983 (parathormone) et 1139 (25-OH-vitamine D).
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2017;7(1):1-59.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : acte 4500 (dépistage et/ou diagnostic d'une hépatite B).